Literature DB >> 17616265

[Psychological and pharmacological treatments of mood and anxiety disorders during pregnancy and postpartum. Review and synthesis].

J Dayan1, K Yoshida.   

Abstract

The aim of this article is to review the main methods of treatment of anxious and depressive disorders during pregnancy and the postpartum. To this end, we analyse recent publications about the use and efficacy of psychotherapy and psychosocial interventions (cognitive behavioural therapy, interpersonal psychotherapy, psychoanalytical therapy) in the perinatal period. We also review recent papers about the use of psychotropic medication during pregnancy and breast-feeding, with special emphasis on clinical trials. We particularly focus on the risk/benefit assessment of antidepressants, mood stabilisers, antipsychotics and benzodiazepines, in terms of teratogenicity, and impact on neonatal adaptation and neuropsychological development. Various treatment modalities are presented and discussed. It appears that psychotherapies have proved their efficiency on most pre- and postpartum anxious and depressive disorders and represent a first line treatment in most cases. Psychopharmacological treatment is indicated for severe anxious and depressive disorders. The risks of such medication, especially antidepressants, may have been overestimated in the past. Provided reasonable precautions are taken and mothers and future mothers receive clear information on the potential risks and benefits, psychotropic medication could be more broadly prescribed during pregnancy and the breast-feeding period.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17616265     DOI: 10.1016/j.jgyn.2007.06.004

Source DB:  PubMed          Journal:  J Gynecol Obstet Biol Reprod (Paris)        ISSN: 0150-9918


  1 in total

1.  Developmental model of depression applied to prenatal depression: role of present and past life events, past emotional disorders and pregnancy stress.

Authors:  Jacques Dayan; Christian Creveuil; Michel Dreyfus; Michel Herlicoviez; Jean-Marc Baleyte; Veronica O'Keane
Journal:  PLoS One       Date:  2010-09-22       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.